Anavex Life Sciences Corp.
Index- P/E- EPS (ttm)-0.59 Insider Own1.70% Shs Outstand77.44M Perf Week-21.78%
Market Cap700.45M Forward P/E- EPS next Y-0.48 Insider Trans0.00% Shs Float75.59M Perf Month-27.08%
Income-45.40M PEG- EPS next Q-0.16 Inst Own32.10% Short Float / Ratio13.45% / 10.59 Perf Quarter-6.19%
Sales- P/S- EPS this Y-20.30% Inst Trans-2.23% Short Interest10.17M Perf Half Y-1.87%
Book/sh1.95 P/B4.58 EPS next Y21.30% ROA-28.40% Target Price35.33 Perf Year-56.26%
Cash/sh1.96 P/C4.57 EPS next 5Y- ROE-30.30% 52W Range7.13 - 21.30 Perf YTD-48.44%
Dividend- P/FCF- EPS past 5Y-5.30% ROI- 52W High-58.03% Beta0.79
Dividend %- Quick Ratio16.90 Sales past 5Y- Gross Margin- 52W Low25.39% ATR1.02
Employees25 Current Ratio16.90 Sales Q/Q- Oper. Margin- RSI (14)31.98 Volatility13.90% 8.63%
OptionableYes Debt/Eq0.00 EPS Q/Q-10.70% Profit Margin- Rel Volume2.27 Prev Close9.10
ShortableYes LT Debt/Eq0.00 EarningsNov 28 BMO Payout- Avg Volume960.54K Price8.94
Recom1.80 SMA20-27.22% SMA50-21.02% SMA200-15.94% Volume2,155,419 Change-1.76%
Jun-23-22Initiated Berenberg Buy $40
Sep-23-21Initiated BTIG Research Buy $35
Dec-16-20Reiterated H.C. Wainwright Buy $14 → $17
Sep-28-20Initiated Ladenburg Thalmann Buy $12
Feb-27-20Initiated Cantor Fitzgerald Overweight
Jun-18-19Initiated Janney Buy
May-16-18Resumed Maxim Group Buy $5 → $7
Mar-08-18Initiated ROTH Capital Buy $6
Feb-13-18Reiterated Maxim Group Buy $14 → $5
Sep-29-17Resumed Noble Financial Buy $15
Show Previous Ratings
Nov-28-22 06:09PM
Nov-23-22 07:00AM
Nov-08-22 07:00AM
07:00AM Loading…
Nov-07-22 07:00AM
Oct-25-22 07:22AM
Oct-17-22 07:00AM
Sep-21-22 07:00AM
Aug-23-22 07:00AM
Aug-16-22 08:30AM
Aug-09-22 10:00PM
Aug-03-22 07:00AM
Aug-02-22 07:00AM
10:00AM Loading…
Jul-31-22 10:00AM
Jul-13-22 09:55AM
Jun-30-22 11:49AM
Jun-27-22 09:55AM
Jun-22-22 09:24AM
Jun-21-22 08:00AM
Jun-10-22 09:55AM
Jun-09-22 10:48AM
Jun-08-22 10:14AM
Jun-07-22 11:30AM
Jun-06-22 10:13AM
Jun-03-22 10:51AM
10:49AM Loading…
May-25-22 09:55AM
May-19-22 07:00AM
May-13-22 04:17PM
May-10-22 07:00AM
May-03-22 07:00AM
Apr-27-22 07:00AM
Apr-26-22 07:00AM
Apr-07-22 07:00AM
Mar-28-22 07:00AM
Mar-15-22 12:04PM
Mar-09-22 07:00AM
Mar-04-22 07:00AM
Feb-10-22 11:30AM
Feb-09-22 07:00AM
Feb-04-22 07:00AM
Feb-03-22 07:00AM
Feb-01-22 06:28PM
Jan-14-22 09:38AM
Jan-10-22 08:12AM
Jan-06-22 07:00AM
Jan-05-22 07:00AM
Dec-29-21 08:42AM
Dec-14-21 07:00AM
Dec-09-21 05:06AM
Dec-02-21 03:30AM
Nov-29-21 07:00AM
Nov-24-21 07:00AM
Nov-17-21 07:00AM
Nov-10-21 07:00AM
Oct-18-21 07:45AM
Oct-15-21 07:00AM
Oct-13-21 07:00AM
Sep-27-21 09:30AM
Sep-20-21 07:00AM
Sep-09-21 07:00AM
Aug-26-21 07:00AM
Aug-19-21 09:49AM
Aug-13-21 06:00AM
Aug-12-21 07:00AM
Aug-05-21 07:00AM
Aug-04-21 07:00AM
Jul-29-21 03:30PM
Jul-27-21 01:24PM
Jul-26-21 01:44PM
Jul-09-21 06:49AM
Jun-29-21 09:34AM
Jun-28-21 12:33PM
Jun-26-21 07:34AM
Jun-24-21 04:15PM
Jun-23-21 11:08AM
Jun-22-21 07:00AM
Jun-21-21 05:37PM
Jun-18-21 10:57AM
Jun-16-21 12:24PM
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Skarpelos AthanasiosDirectorMay 25Option Exercise0.9250,00046,0001,356,458May 27 08:30 PM
Skarpelos AthanasiosDirectorMay 25Sale9.0650,000453,0001,306,458May 27 08:30 PM